1. Kluger J, Drayer DE, Redenberg MM, Lahita R. Acetylprocainamide therapy in patients with previous procainamide-induced lupus. Ann Intern Med 1981; 95: 18-23.
2. Roden DM, Reele SB, Higgins SB, Wilkinson GR, Smith RF, Oates JA, Woosley RL. Antiarrythmic efficacy, pharmacokinetics and safety of N- acetylprocinamide in human subjects. Comparison with procainamide. Am J Cardiol 1980; 46: 463-468.
3. Atkinson AJ. Lertora JJL. Kushner W, Chao GC, Nevin MJ. Efficacy and safety of N- acetylprocainamide in long-term treatment of ventricular arrhythmias. Clin Pharm Ther 1983; 33: 565-576.
4. Lertora JJL. Atkinson AJ Jr. Kushner W, Nevin MJ, Lee WK, Jones C, Schmid FR. Long term antiarrythmic therapy with N-acetylprocainamide. 1979; 25: 273-282.
5. Medical Economics Co. Montvale, NJ. Physicians' Desk Reference 1996.
6. Mancuso G,Tampieri E, Berdondini RM. Psoriasis-like eruption caused by flecainide. G Ital Dermatol Venereol 1988; 123: 171-172.
7. Palace J, Shah R, Clough C. Flecainide induced peripheral neuropathy. Br Med J 1992; 305: 810.
8. Bricker SR, Raitt DG. Angioneurotic edema following etomidatelignocaine. Anaesthesia 1987; 42: 323-324.
9. Black RJ, Dawson TA, Strang WC. Contact sensitivity to lignocaine and prilocaine. Contact Dermatitis 1990; 23:117-118.
10. Silverman AK, Fairley J, Wong RC. Cutaneous and immunologic reactions to phenytoin. J Am Acad Dermatol 1988; 18: 721-741.
11. Vivard I, Trechot P, Schmutz JL,Cuny JF, Weber M, Beurey J. Phenytoin and hirsutism. Ann Dermatol Venereol 1989; 116: 562.
12. Kleier RS, Sreneman DL, Boiko S. Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch Dermatol 1991; 27:1361-1364.
13. Rowe JE, Pina J, Sau P, James W. Toxic epidermal necrolysis associated with diphenylhydantoin and cranial irradiation. Int J Dermatol 1991; 30: 747-749.
14. Kelly DR, Hope DG. Fatal phenytoin-related toxic epidermal necrolysis. Case report. Neurosurgery 1989; 25: 976-978.
15. Gately LE, Lam M. Phenytoin-induced toxic epidermal necrolysis. Ann Intern Med 1979; 91: 59-60.
16. Schreiber MM, McGregor JG. Pseudolymphoma sydrome: Asensitivity to Anticonvulsant drugs. Arch Dermatol 1968; 97: 297-300.
17. Norris JF, Cunliffe WJ.Phenytoin-induced gum hypertrophy improved by isoretinoin. Int J Dermatol 1967; 26:602-603.
18. McLoughlin P, Newman L, Brown A. Oral squamous cell carcinoma arising in phenytoin-induced hyperplasia. Br Dent J 1995; 178: 183-184.
19. MacDonal E, Marino C. Procainamide-induced lupus in the elderly. Hosp Pract (Office ed.) 1993; 228: 95-98.
20. Knox JP, WelykyJ SE, Granidi R, Massa MC. Procainamide-induced urticarial vasculitis. Cutis 1988; 42:51-53.
21. Guindo J, Rodriguez A, Borja J. Propafenone and a syndrome of the lupus erythematosus type. Ann Intern Med 1986; 104:589.
22. Pariser DM, Taylor JR. Quinidine photosensitivity. Arch Dermatol 1975; 111: 1440-1443.
23. Taylor DR, Potashnick R. Quinidine-induced exfoliative dermatitis. JAMA 1951; 145: 641-642.
24. Nudelman PL, Leff IL, Howe CD. Thrombocytopenic purpura following quinidine. JAMA 1948; 137: 1219-1220.
25. Arrowsmith JB, Creamer JI, Bosco L. Severe dermatologic reactions reported after treatment with tocainide. Ann Intern Med 1987; 107: 693-696.
26. Dunn JM, Groth PE, DeSimone A. Tocainidine: A severe adverse reaction. Drug intell Clin Pharm 1988; 22: 142-145.
27. Duff HJ, Roden DM, Marney S, Colley DG, Maffucci R, Primm RK, Oates JA, Woosley RL. Molecular basis for the antigenicity of lidocaine analogs: Tocainide and mexilitine. Am Heaart J 1984; 107: 585-589.
28. Cody RJ, Calabrese LH, Clough JD, Tarazi RC, Bravo EL. Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Ther 1979; 25: 800-805.
29. Wolf R, Ophir J, Elman M, Krakowski A: Atenolol-induced cutaneous vasculitis. Cutis 1989; 443: 231-233.
30. Goral R, Dorman TL, Ledingham JGG: Peripheral skin necrosis complicating beta blockage. Br Med J 1979; 1: 721-722.
31. Staughton R, Sutton R, Farrel M: Beta blockers, autoimmunity and rashes. Lancet 1980: 2: 581.
32. Almedya J, Levantine A. Cutaneous reactions to cardiovascular drugs. Br J Derm 1973; 88: 313-319.
33. Grance RW, Jones EW. Bullous lichen planus caused by labetalol. Br Med J 1979; 2: 496-497.
34. Neumann Ham, Van Joost T. Adverse reactions of the skin to metoprolol and other beta-adrenoreceptor blocking agents. Dermatologica 1981; 162: 330-335.
35. Leonard JC. Oxprenolol and a psoriasis-like eruption. Lancet 1975; 1:6 30.
36. Harrower ADB, Strong JA. Hyperpigmentation associated with oxprenolol. Br Med J 1975; 2: 539-540.
37. Holt PJA, Waddington E. Oculocutaneous reaction to oxprenolol. Br Med J 1975; 2: 539-540.
38. Waal-Manning HJ. Problems with practolol. Drugs 1975; 10: 336-341.
39. Hu CH, Peppercorn R, Farber EM. Generalized pustular psoriasis provoked by propranolol. Arch Dermatol 1985; 212: 1326-1327.
40. Mukul VG, Verma G. Propranolol-induced Stevens-Johnson syndrome from maprotiline and propranolol. 1989; Assoc Phys India 37: 797-798.
41. O'Brien TJ, Lvam IG, Reid SS. Lichenoid eruption by sotalol. Aaustralas J Dermatol 1994; 35: 93-94.
42. Rappersberger K, Honigsmann H, Ortel B, Tanew A, Konrad K, Wolff KJ. Photosensivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. Invest Dermatol 1989; 93: 201-209.
43. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J 1991; 121-158.
44. Feigi D, Gilard R, Kaatz E. Complications of low-dose amiodarone. 1991; 121: 374-377.
45. Reifler DM, Vedier DD, Davy CL. Multiple chalazia and rosacea in a patient treated with amiodarone. Am J Ophthalmol 1987; 103: 594-595.
46. Staubi M Zimmermann A, Bircher J. Amiodarone-induced vasculitis and polyserositis. Postgrad Med J 1985; 61: 245-247.
47. Porters JE, Zantkuyl CF. Ioderma caused by amiodarone. Arch Dermatol 1975; 111: 1656.
48. Khanderia U, Jaffe CA, Theisen V. Amiodarone-induced thyroid dysfunction. Clin Pharm 1993: 2; 774-779.
49. Trif MD, Wiersinga W,Plomp TA. İncidence, predictability, and patogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991: 91; 507-511.
50. Seymour RA. Calcium channel blockers and gingival overgrowth. Br Dent J 1991: 170; 376-379.
51. Seymour RA, Ellis JS, Thomason JM. Amlodipin-induced gingival over growth. J Clin Periodontol 1994: 21; 281-283.
52. Dacosta A, Mismetti P, Tardy B. Non-thrombopenic purpura induced by amlodipine. Therapie 1994; 49: 515-517.
53. Janier M Gerault MH, Carlotti A, Vignon MD, Daniel F. Acute generalized exanthematous pustulosis due to diltiazem. Br J Dermatol 1993; 129: 354-355.
54. Sanders CJ, Neumann HA. Erythema multiforme, Stevens-Johnson syndrome, and diltiazem. Lancet 1993; 341: 967.
55. Reynolds NJ, Jones SK, Crossley J, Harman RR. Exfoliative dermatitis due to nifedipine. Br J Dermatol 1989; 121: 401-404.
56. Kürkçüoğlu N, Alaybeyi F. Erythema multiforme after verapamil treatment. J Am Acad Dermatol 1991; 24: 511-512.
57. Griffth MJ, Ward DE, Linker NJ, Camm AJ. Adenosine in the diagnosis of broad complex tachycardia. Lancet 1988; 1: 672-675.
58. Overholt ED, Rheuban KS, Gutgesell HP, Lerman BB, Dimarca JP. Usefulness of adenosine for arrhythmias in infants and children. Am J Cardiol 1988; 61: 336-340.
59. David M, Livni E, Stern E, Feuerman EJ, Grinblatt J. Psoriasiform eruption induced by digoxin: confirmed by re-exposure. J Am Acad Dermatol 1981; 5: 702-703.
60. Chu TJ, Crow N. Adverse effects of ACE inhibitors. Ann Intern Med 1993; 118: 314-315.
61. Kaplan RP, Potter TS, Fox JN. Drug-induced pemphigus related to angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 1992; 26; 364-366.
62. Bertin P, Kamdem J, Bonneet C. Captopril-induced lupus. Clin Exp Rheumatol 1993; 11: 695.
63. Larbre JP, Nicolas JF, Collet P, Larbre B, Liorca G. Kaposi's sarcoma in a patient with rheumatoid arthritis possible responsibility of captopril in the development of lesions. J Rheumatol 1991; 18: 476-477.
64. Llop R, Gomez- Farran F, Figueras A. Gynecomastia associated with enalapril and diazepam. Ann Pharmacother 1994; 28: 671-672.
65. Shelton RM. Pemphigus foliaceous associated with enalapril. J Am Acad Dermatol 1991: 24; 503-504.
66. Bielory L, Lee SS, Holland CL, Jaker M. Long-acting ACE-inhibitor angioedema. Aller Proc 1992; 13: 85-87.
67. Rees RS, Bergman J, Ramirez-Alexander R. Angioedema associated with lisinopril. Am J Emerg Med 1992; 10: 321-322.
68. Acker CG, Greenberg A. Angioedema induced by the angiotensin II blocker losartan. N Engl J Med 1995; 333: 1572.
69. Cernek PK. Dermal cellulitis-a hypersensitivity reaction from dobutamine hydrochloride. 1994: 28; 964.
70. Bork K. Cutaneous Side Effects of Drugs. Philadelphia, WB Saunders Co, 1988; 3-18.
71. McCauley WA, Gerace RV, Scilley C. Treatment of accidental digital injection of epinephrine. Ann Emerg Med 1991: 20; 665-668.
72. Gibson TP, Blue P. Erythema multiforme and furosemide therapy. JAMA 1970; 212: 1709.
73. Fellner MJ, Katz JM. Occurence of bullous pemphgoid after furosemide therapy. Arch Dermatol 1976; 122: 75-77.
74. Wollenberg A, Meurer M. Thiazide diuretic-induced subacute cutaneous lupus erythematosus. Hautarzt 1991; 42: 709-712.
75. Biornberg A, Gisslen H. Thiazides: A cause of necrotizing vasculitis? Lancet 1965; 2: 982-983.
76. Danby FW. Spironolactone. J Am Acad Dermatol 1992; 26: 137.
77. Baume P, Ratcliffe FJ, Corry JR: Triamterene, a new natriuretic agent. Am J Med Sci 1963; 245: 668-675.
78. Witman G, Davis R. A lupus erythematosus syndrome induced by clonidine hydrochloride. RI Med J 1980; 102: 147-150.
79. Kuan P. Dangers of diazoxide. Br Med J 1973; I: 114.
80. Yonga GD. Low dose hydralazine induced lupus. East Afr Med J 1992; 69: 649-650.
81. Peterson II. Hydralazine-induced systemic lupus erythematosus presenting as pyoderma gangrenosum-like ulcers. J Am Acad Dermatol 1984; 10: 379-380.
82. Vaillant L, Le Maarchand D, Grognard C, Hocine R, Lorette G. Photosensitivity to methyldopa. Arch Dermatol 1988: 124; 326-327.
83. Wells JD, Kurtay M, Lochner JC. Granulomatouus skin lesions and alpha-methyl dopa. Ann Intern Med 1974: 81; 701-702.
84. Burton JL, Marchall A. Hyperthrichosis due to minoxidil. Br J Dermatol 1979; 101: 593-595.
85. DiSantis DJ, Flanagan J. Minoxidil-induced Stevens-Johnson syndrome. Arch Intern Med 1981; 141: 1515.
86. De La Fuente Prieto R, Armentia Medina A, Diez Perez JM. Contact dermatitis from nitroglycerin. Ann Allergy 1994; 72: 344-346.
87. Baker H, Moore-Robinson M. Cutaneous responses to aspirin and its derivatives. Br J Dermatol 1970; 82: 319-321.
88. Brannen M, Forbes AF. Salicylate sensitivity. Tex J Med 1966; 62: 58-60.
89. Shelley WB. Birch pollen and aspirin psoriasis. JAMA 1964; 189: 985-988.
90. Phillips DE, Payne DK, Millis GM. Heparin induced thrombotic thrombocytopenia Ann Pharmacother 1994; 28: 43-46.
91. Kelly RA, Gelfand JA,Pincus SH. Cutaneous necrosis caused by sytemically administered heparin. JAMA 1981; 246: 1582-1583.
92. Gold JA, Watters AK, O'Brien E. Coumadin versus heparin necrosis. J Am Acad Dermatol 1987;16: 148-149.
93. Real E, Grau E, Rubio M, Torrecilla T. Skin necrosis after subcutaneous low molecular weight heparin injection. Am J Haematol 1995; 49: 253-254.
94. Ojeda, E, Perez MC, Mataix R, Arbelo A, Jimenez S, Campo C, Balda I. Skin necrosis with a low molecular weight heparin. Br J Haematol 1992; 82: 620.
95. Humpries JE, Kaplan DM, Bolton WK. Heparin skin necrosis: delayed occurrence in a patient on hemodialysis. Am J Kidney Dis 1991; 17: 233-236.
96. Bircher AJ, Itin PH, Buchner SA. Skin lesions, hypereosinophilia, and subcutaneous heparin. Lancet 1994; 342: 1371.
97. Sternberg MC, Pettyjohn FS. Warfarin sodium-induced skin necrosis. Ann Emerg Med 1995; 26: 94-97.
98. Baker H, Levene GM. Cutaneous reactions to anticoagulants. Br J Dermatol 1969; 81: 236-238.
99. Wong SS. Stevens-Johnson syndrome induced by clofibrate. Acta Derm Venereol 1994; 74: 475.
100. Smith GW, Hurst NP. Vasculitis, Raynaud's phenomenon, and polyarthritis associated with gemfibrozil therapy. Br J Rheum 1993; 32: 84-85.
101. Ahmed S. Lovastatin-induced lupus erythematosus. Arch Intern Med 1991; 151: 1667-1668.
102. Stals H, Vercammen C, Peeters C. Morren MA. Acanthosis nigracans caused by nicotinic acid: Case report and review of the literature. Dermatology 1994; 189: 203-206.
103. Charman RC, Matthews LB, Braculer C. Nicotinic acid in the treatment of hypercholesterolemia. Angiology 1972; 23: 29-35.
Thank you for copying data from http://www.arastirmax.com